Table 1. Summary of varied PFFs used in M83^+/− IM injection experiments.

Each cohort is shown along with composition and dosage of injected PFFs, age of animals at injection, mean ± standard deviation and median days post-injection until motor phenotype onset. Dosages of C-truncated αsyn PFFs or C-truncated/FL αsyn mixed PFFs were chosen to be molar equivalent to the control 5 μg FL αsyn PFFs.

Cohort	Inoculum	N	Age at Injection (months)	Mean Survival Post-Injection ± std (days)	Median Survival Post-Injection (days)
Dosage
0.1 μg	0.10 μg mPFFs	11	2	164±31	159
0.5 μg	0.50 μg mPFFs	13	2	146±37	136
1 μg	1.00 μg mPFFs	11	2	149±31	134
2 μg	2.00 μg mPFFs	8	2	142±26	128
5 μg	5.00 μg mPFFs	8	2	133±11	135
10 μg	10.00 μg mPFFs	8	2	126±13	127
Sex
Male	0.50-10.00 μg mPFFs	24	2	138±32	131
Female	0.50-10.00 μg mPFFs	24	2	143±25	135
C-terminal modification
1-115	4.00 μg 1-115 hPFFs	11	2	211±37	205
1-119	4.15 μg 1-119 hPFFs	10	2	241±58	213
1-122	4.26 μg 1-122 hPFFs	10	2	176±38	186
1-125	4.39 μg 1-125 hPFFs	10	2	170±37	171
1-129	4.55 μg 1-129 hPFFs	10	2	212±46	199
1-140 (FL)	5.00 μg FL hPFFs	12	2	121±23	115
S129E	5.00 μg S129E hPFFs	10	2	153±22	146
1-115/FL	4.50 μg 1-115/FL hPFFs	11	2	144±35	142
1-119/FL	4.58 μg 1-119/FL hPFFs	10	2	173±58	147
1-122/FL	4.63 μg 1-122/FL hPFFs	10	2	149±23	148
1-125/FL	4.70 μg 1-125/FL hPFFs	10	2	131±22	134
1-129/FL	4.78 μg 1-129/FL hPFFs	9	2	124±14	125